Skip to main content
Premium Trial:

Request an Annual Quote

When a Pat on the Back Just Isn't Enough

"Do you do science to win awards?" asks NeuroDojo's Zen Faulkes. Awards can become a "problem" in science if they are the only motivation for some people to do research, he says. It's certainly nice to get an award and be recognized for all your hard work, but it shouldn't be a driving force. Awards like the Nobel Prize that come with lots of money and prestige attached are particularly troublesome because money shouldn't be the point of science, he adds. "It's a matter of means, ends, and side effects. To me, the end goal of science should be good evidence, strong predictions, and less ignorance about the world," Faulkes says. "Money is a means to the end. Awards are a side effect."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.